Diagnostic Performance of APRI and FIB-4 for Confirming Cirrhosis in Indonesian HIV/HCV Co-infected Patients
Background: After successful of antiretroviral therapy, highly effective direct acting antiviral (DAA) make HCV elimination reasonable in HIV/HCV co-infected patients. However, in achieving this target, there are still barriers to start DAA treatment, particularly in the area of liver fibrosis assessment that determine the duration of therapy. We aimed to assess the diagnostic performance of APRI and FIB-4 for diagnosing cirrhosis in HIV/HCV co-infected patients using hepatic transient elastography (TE) as gold standard.
Method: This is a retrospective study on HIV/HCV co-infected patients who concomitantly performed hepatic TE measurement, APRI, and FIB-4 evaluation before HCV treatment initiation at a tertiary hospital in Jakarta from 2014 to 2019. Sensitivity, specificity and diagnostic accuracy of indirect biomarkers for liver stiffness measurement (LSM) ≥ 12.5 kPa was determined by receiver operator characteristics curves.
Results: 223 HIV/HCV co-infected patients on stable antiretroviral therapy were included, of whom 91.5% were male with mean age of 37 (SD 5) years. Only 28.7% of patients were classified as cirrhosis (F4). Using TE as gold standard (≥12.5 kPa), the low threshold of APRI (1) had specificity 95%, sensitivity 48.4%, correctly classified 81.6% of patients, with moderate performance, AUC at 0.72 (95% CI 0.63-0.80). The optimal cut-off of FIB-4 was 1.66 [specificity 92.5%, sensitivity 53.1%, AUC at 0.73 (95% CI 0.65-0.81)] and correctly classified 81.1% of the patients.
Conclusion: APRI score > 1 and FIB-4 score > 1.66 had moderate performance with high specificity in diagnosing cirrhosis. These biochemical markers could be used while TE is not available.
Figure 1
Posted 16 May, 2020
On 08 Jan, 2020
On 29 Apr, 2020
On 19 Apr, 2020
On 18 Apr, 2020
On 18 Apr, 2020
On 23 Mar, 2020
On 15 Mar, 2020
On 14 Mar, 2020
On 14 Mar, 2020
On 28 Feb, 2020
Received 27 Feb, 2020
Received 18 Feb, 2020
On 10 Feb, 2020
On 07 Feb, 2020
On 06 Feb, 2020
Received 06 Feb, 2020
Received 04 Feb, 2020
On 21 Jan, 2020
Invitations sent on 14 Jan, 2020
On 27 Dec, 2019
On 26 Dec, 2019
On 26 Dec, 2019
On 26 Dec, 2019
Diagnostic Performance of APRI and FIB-4 for Confirming Cirrhosis in Indonesian HIV/HCV Co-infected Patients
Posted 16 May, 2020
On 08 Jan, 2020
On 29 Apr, 2020
On 19 Apr, 2020
On 18 Apr, 2020
On 18 Apr, 2020
On 23 Mar, 2020
On 15 Mar, 2020
On 14 Mar, 2020
On 14 Mar, 2020
On 28 Feb, 2020
Received 27 Feb, 2020
Received 18 Feb, 2020
On 10 Feb, 2020
On 07 Feb, 2020
On 06 Feb, 2020
Received 06 Feb, 2020
Received 04 Feb, 2020
On 21 Jan, 2020
Invitations sent on 14 Jan, 2020
On 27 Dec, 2019
On 26 Dec, 2019
On 26 Dec, 2019
On 26 Dec, 2019
Background: After successful of antiretroviral therapy, highly effective direct acting antiviral (DAA) make HCV elimination reasonable in HIV/HCV co-infected patients. However, in achieving this target, there are still barriers to start DAA treatment, particularly in the area of liver fibrosis assessment that determine the duration of therapy. We aimed to assess the diagnostic performance of APRI and FIB-4 for diagnosing cirrhosis in HIV/HCV co-infected patients using hepatic transient elastography (TE) as gold standard.
Method: This is a retrospective study on HIV/HCV co-infected patients who concomitantly performed hepatic TE measurement, APRI, and FIB-4 evaluation before HCV treatment initiation at a tertiary hospital in Jakarta from 2014 to 2019. Sensitivity, specificity and diagnostic accuracy of indirect biomarkers for liver stiffness measurement (LSM) ≥ 12.5 kPa was determined by receiver operator characteristics curves.
Results: 223 HIV/HCV co-infected patients on stable antiretroviral therapy were included, of whom 91.5% were male with mean age of 37 (SD 5) years. Only 28.7% of patients were classified as cirrhosis (F4). Using TE as gold standard (≥12.5 kPa), the low threshold of APRI (1) had specificity 95%, sensitivity 48.4%, correctly classified 81.6% of patients, with moderate performance, AUC at 0.72 (95% CI 0.63-0.80). The optimal cut-off of FIB-4 was 1.66 [specificity 92.5%, sensitivity 53.1%, AUC at 0.73 (95% CI 0.65-0.81)] and correctly classified 81.1% of the patients.
Conclusion: APRI score > 1 and FIB-4 score > 1.66 had moderate performance with high specificity in diagnosing cirrhosis. These biochemical markers could be used while TE is not available.
Figure 1